RICHMOND: Indivior PLC (Nasdaq/LSE: INDV) announced Tuesday its plans to cancel its secondary listing on the London Stock Exchange, consolidating its primary listing on Nasdaq as the company shifts focus to its U.S. operations.
The pharmaceutical firm, known for its addiction treatment SUBLOCADE, said the move reflects its revenue concentration in the U.S., where over 80% of net revenue is generated. The delisting is expected to take effect July 25, 2025, with the last trading day in London on July 24.
Indivior’s board cited several reasons for the decision, including:
– Reduced liquidity on the LSE, with Nasdaq now accounting for about 75% of trading volume.
– More than 70% of shareholders by value are based in the U.S.
– Cost savings from eliminating dual listing requirements.
“A single primary listing on Nasdaq best reflects the profile of Indivior’s business,” said Chair David Wheadon. “We appreciate shareholder support and look forward to the expected benefits.”
The company noted that holders of U.S.-traded shares will see no impact, while U.K. investors holding depositary interests may need to convert their holdings to trade on Nasdaq. No shareholder approval was required for the delisting.
Indivior transitioned to a U.S. primary listing in 2023. Its shares will continue trading under “INDV” on Nasdaq.